Josh Enomoto

Josh Enomoto

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Don’t Miss the Boom: 3 Transportation Stocks Set to Explode Higher

Although a risky wager, contrarians that want to gamble on an economic comeback may consider these transportation stocks to buy.

7 Stocks Analysts Predict Have 100% Upside

While you always need to conduct your own due diligence, these analyst-backed stocks with upside potential could double in value.

Carnival Just Reported Record Revenue. Why Is CCL Stock Down?

Although Carnival posted blistering stats for its Q3 earnings report, investors hit the exits on CCL stock due to projected concerns.

Bumble (BMBL) Stock Pops 5% on Loop Capital Upgrade

Although dating app Bumble received a lift from a Loop Capital upgrade, BMBL stock must still contend against bearish traders.

Ticking Time Bombs: 3 Blue-Chip Stocks to Dump Before the Damage Is Done

Although established entities enjoy a strong track record, these blue-chip stocks to sell prove that they’re not immune from risks.

Don’t Miss the Boom: 7 Utilities Stocks Set to Explode Higher

With the market offering few reliable opportunities, investors should go the cynical route with these utilities stocks to buy.

7 Contrarian Stocks to Buy for the High-Stakes Gambler

With limited options available as the market rotates out of risk-on assets, speculators may try their luck with contrarian stocks to buy.

NVAX, AI, CVNA: The 3 Most Shorted Stocks This Month

With the market suffering losses due to broader headwinds, hedge funds have targeted the most shorted stocks for cynical profits.

Why Is Baudax Bio (BXRX) Stock Up 75% Today?

Although Baudax Bio saw significant interest because of its orphan drug designation, BXRX stock must climb a wall of worry.

Don’t Miss the Boom: 3 Oil Stocks Set to Explode Higher

Despite the seeming lack of relevance, these oil stocks to buy confirm that hydrocarbons still have their place in the energy ecosystem.